Nanoparticles for drug delivery: next-generation biological drugs to treat inflammatory bowel diseases

Nanoparticles offer a promising alternative to conventional drug delivery that allow for more precise targeting and controlled release. Here, Dr Fabrice Navarro discusses the benefits of these nanocarriers and their potential as a therapy for inflammatory bowel diseases (IBDs).

Cartoon of a hand under an anatomical diagram of the large intestines

INFLAMMATORY BOWEL DISEASES (IBDs) are chronic, immune disorders of the gastro-intestinal tract with an early onset in life.1,2 Conventional therapeutics like corticosteroids and the first generation of biological drugs, therapeutic antibodies, are effective only for subsets of patients and some patients can lose response over time.3 In light of this, there is an urgent need for more effective therapies.

    To read this article in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Catalent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend